Whereas activation of the CREBH–Fgf21 axis protects mice from HFD-induced obesity, IR, and hepatic steatosis (6, 7), the current study was designed to explore whether its activation would reverse these disorders once established. Here, FGF21 is linked to fatty liver disease.